XTX Topco Ltd Purchases 18,012 Shares of Johnson & Johnson (NYSE:JNJ)

XTX Topco Ltd grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 171.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,510 shares of the company's stock after purchasing an additional 18,012 shares during the quarter. Johnson & Johnson makes up approximately 0.3% of XTX Topco Ltd's portfolio, making the stock its 17th biggest position. XTX Topco Ltd's holdings in Johnson & Johnson were worth $4,123,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. IFS Advisors LLC lifted its stake in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson in the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $32,000. Finally, Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $33,000. Institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Remove Ads

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Bank of America decreased their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Eight analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $171.50.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $0.71 during trading hours on Tuesday, hitting $153.66. The company's stock had a trading volume of 10,723,823 shares, compared to its average volume of 7,973,459. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The business has a 50 day moving average price of $159.38 and a two-hundred day moving average price of $155.11. The company has a market cap of $370.29 billion, a PE ratio of 23.11, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.